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Abstract
Introduction The objective of this study was to identify
cancer-associated protein expression patterns in bilateral
matched nipple aspiration fluids using nanoscale reciprocal
Cy3/Cy5 labeling and high-content antibody microarrays.
This novel platform allows the pair-wise comparisons of the
relative abundance of 512 different antigens using minimal
NAF sample containing 1 µg of total protein.
Material and Methods Matched NAF samples from two
normal controls and 18 patients with early stage breast
cancer (stage I/II, 13; DCIS, 2) or precancerous lesions
(ADH, 3) were studied. Self-to-self and left-to-right
comparisons of the normal controls were performed to
determine antigen variations due to normal experimental
and biological variability. Based on these two experiments,
a stringency filter of 15% was applied to eliminate noise.
Antigens were considered differentially expressed if there
were a consistent >15% change on relative Cy3/Cy5 signals
on reciprocal slides.
Results and Discussion The number of differentially
expressed antigens varied between 10 and 72 in tumor
associated NAF samples, and no single antigen can be used
as a “universal” marker to identify all patients. Antigens
that are elevated in at least four patients were selected for
further evaluations, including NME1, PTK2B, ARRB1,
MRIP, GFRA1, APC, HSPD1, and SLP76. The validity of
the antibody array findings was affirmed by single
immunoassay on western blot; elevated expression of four
of the selected markers in NAF is supported by published
immunohistochemistry studies on breast cancer tissues.
Conclusions Nipple aspiration fluid is a rich source of breast
cancer biomarkers. This targeted proteomics approach for
biomarker discovery is proven effective for clinical samples
with limited protein content.
Keywords Breast cancer . Biomarker . Nipple aspiration
fluid . Antibody microarray . Proteomics
Introduction
The human mammary gland is composed of discrete
ductal–alveolar systems that originate at the nipple and
branch through the surrounding stroma toward the chest
wall. The majority of breast carcinomas arise from the
epithelial cells that are lining the terminal ducts. As a
renewal tissue, the breast epithelium exfoliates cells and
secretes fluid into the luminal compartment of the gland,
and this fluid can be collected noninvasively by nipple
aspiration. In nipple aspiration, a simple handheld suction
cup is placed on the nipple and used to quickly obtain
concentrated fluid droplets at nipple openings. This
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procedure is noninvasive and is successful in most
nonpregnant/nonlactating women [1], with the typical yield
of fluid volume between several to several hundred micro-
liters, protein content between several to several hundred
micrograms [2–5].
Compared to serum, breast fluids potentially offer a
superior source of biomarkers for breast cancer as the
proteins are directly sampled from the tumor microenvi-
ronment, highly concentrated, and yet with a protein
composition much less complex. The potential drawback is
limitation on fluid volume. Pooled samples are often required
to afford comprehensive proteomics analysis [6, 7]. Using
Liquid Chromatography and Tandem Mass Spectrometry
(LC-MS/MS), Varnum et al. [8] reported the identification of
64 proteins in NAF pooled from healthy volunteers, the
largest number of proteins identified so far in NAF.
The unique feature of the breasts as paired organs allows
a direct comparison between the affected and unaffected
breasts of the same cancer patient. This could substantially
minimize the biological variability between individuals and
the same women at different time of her physiological
cycle. For this reason, sample pooling should be avoided
provided that the proteomics platform is sufficiently
sensitive for protein samples at microgram level. To avoid
pooling of the samples, we and several other groups have
explored the utility of SELDI. SELDI is a protein chip
array-based mass spectrometry method. Compared to the
classical LC-MS/MS method, this platform has the advan-
tage of minimal sample requirement (1–4 µg), the disad-
vantage of its inability to provide immediate protein
identifications. As protein identification requires separate
effort, and is time consuming, the number of candidate
proteins identified through this approach is small. In fact,
among the several studies that described differentially
expressed protein peaks [9–11], we are the only group
reporting protein identification (human neutrophil peptide
1–3 [4], fragment of alpha-antitrypsin inhibitor (unpub-
lished result)). Protein identification is not only important
in understanding the underlying mechanism of the potential
biomarker, but also important in the development of
antibody based immunoassays, which is the commonly
adopted test format for tumor biomarkers in clinical
practice.
Limited by the number of proteins we could characterize
using SELDI, we have turned to a targeted proteomics
approach that allows the direct analysis of unpooled NAF
specimens for biomarker discovery. This is the high-content
Antibody Microarray developed by Clontech. The array in its
current format consists of 512 distinct monoclonal antibodies
covalently coupled to a glass slide; each antibody serves as
bait for its specific target antigen (You can obtain the list of
antibodies on http://www.clontech.com/images/brochures/
FL943083_Antibodies_List_FL.pdf).
The initial selection of these antibodies among a large
pool of available antibodies was based on their antigen
specificity, sensitivity (limit of detection), liner response
(the ability of the antibody to detect changes in antigen
abundance), and antibody function when printed on glass
slide. At present, this is the highest content antibody array
commercially available. Designed as a screening tool for
correlating proteins with a physiological or pathological
process, the targets of the printed antibodies on the
Antibody Microarray represent a broad range of biological
functions, including signal transduction, cell-cycle regula-
tion, gene transcription, apoptosis, cell growth, oncogene-
sis, and neuron development.
The Clontech Antibody Microarray was first available in
2003. It was not suitable for analysis of NAF specimens
until its recent development of the nanoscale labeling kit.
The regular labeling protocol requires approximately 1 mg
of total protein, and the yield of protein in NAF specimens
is often in the range of several to hundred micrograms. The
new nanoscale kit uses FluorTrap Matrix Technology to
purify fluorescently labeled proteins from as few as 1,000
cells (microgram level). None of the other technologies
would allow us to obtain relative abundance of such a wide
variety of proteins using this little sample.
Taking advantage of this technology advancement, we
were able to compare on the same antibody array the relative
abundance of 512 proteins in matched NAF from cancer
patients, using 1 µg of protein from each specimen. The
reciprocal labeling of paired samples allowed us to select
candidate biomarkers with higher confidence; the potential
biomarkers identified through this approach were presented.
Materials and Methods
Patients
We obtained NAF samples from a clinical trial that
involved four local breast centers: Breast Center at Johns
Hopkins, Breast Imaging Center at Johns Hopkins, The
Hoffberger Breast Center at Mercy Hospital, and Breast
Imaging Center at Johns Hopkins Greenspring Station. The
eligibility criteria were as follows: age 18–55 (we have
found that our success in obtaining NAF decreases
dramatically after age 55), no previous cancer other than
nonmelanoma skin cancer, not currently pregnant, at least
12 months since the patient ceased breast-feeding, not
taking hormone replacement therapy, no previous breast
reduction or augmentation surgery, capable of providing
informed consent. Controls were enrolled from the two
breast imaging clinics after a normal mammogram.
We performed antibody microarray analysis on the
matched samples of 20 individuals, including patients with
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invasive cancer (stage I/II, 13), DCIS [2], ADH [3], and
normal controls [2] (Table 1). Additional clinical informa-
tion (when applicable) not listed in the table includes: age,
weight, height, education, race, family history, medical
history of breast related disease, tumor size, Elston Grade,
mBR score, pT, pN, pM, Node status, and status of ER, PR,
and Her2.
Nipple Aspiration Procedure
The Research Coordinator obtained NAF from patients in
the above clinics using well-established methods [12–14]
that we have successfully employed in previous studies. A
modified breast pump was used, comprised of a finely
polished clear plastic cup with a Luer-lok end attached
directly to a 20-ml syringe. The cup has an adhesive pad
that helps it stay on the breast prior to application of suction
(FirstCyte, Inc., Boxborough, MA, USA).
Before aspiration was attempted, the nipple was cleansed
with Cerumenex, a solvent used to dissolve earwax (which,
like NAF, is an apocrine secretion). This helped to dissolve
keratin plugs that normally block the duct openings. A
warming pad heated in a microwave was placed over the
breast while the questionnaire was filled out, which helped
increase flow of NAF. The pad was removed, and the
woman was instructed to massage her breast (using hand
lotion on her hands) for 5 min, starting at the base of the
breast, encircling with both hands, and massaging toward
the nipple (taking care not to get lotion on the nipple). The
cup was placed over the cleansed nipple of the breast, and
the woman compresses her breast with both hands while the
plunger of the syringe is withdrawn to 10 ml and held for
8–10 s. Droplets of fluid that appeared at any duct openings
on the nipple were collected into capillary tubes. Three
attempts of 8–10 s each were made to obtain fluid. NAF
was immediately blown into an Eppendorf tube containing
100 μl phosphate-buffered saline (pH 7.4), and the tube
was vortexed. The process was repeated on the other breast,
and the samples were stored in separate labeled tubes. The
volumes of NAF were recorded for each patient and each
breast. All samples were kept on ice after collection and
were transferred to a −80°C freezer within 4 h of sampling.
Antibody Array Analysis
Nanoscale reciprocal labeling and array analysis were
performed according to the manufacturer’s instruction
(Clontech). Modifications made on the original protocol
included adjustment on amount of NAF protein, amount of
FluorTrap Matrix for dye removal, as well as length of
incubation and washing steps to achieve optimal signal-
to-noise ratio. Briefly, 1 µg of each of the paired NAF
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and Cy5 (red fluorescent dye). The labeling mix were
combined (A-Cy3 with B-Cy5, A-Cy5 with B-Cy3),
mixed with FluorTrap Matrix to remove the unbound
dye, and the labeled proteins were recovered by passing
the mixture through a 0.22-µm spin filter. After incubation of
labeled proteins with antibody arrays, the unbound proteins
were washed, and the arrays were scanned using GenePix
4000 scanner.
Data Analysis
The data were analyzed using Nanoscale workbook
provided by Clontech. The ratios, A-Cy3sum/B-Cy5sum
from the first slide and B-Cy3sum/A-Cy5sum from the
second slide, were used to normalize differences due to
inherent variations in dye labeling, respectively. After
normalization, relative signal intensity between Cy3 and
Cy5 on each spot represents the relative abundance of the
target antigen in the paired samples. For each antibody, four
data points were available, duplicate spots on the same
slide, and two slides for each sample pair. The quality of the
data was evaluated by degree of consistency between
duplicate spots and between slides. Differential analysis
between sample A and B was performed at different
stringency settings. The recommended low stringency
setting represents >10% difference observed on one of the
two slides, medium stringency setting represents >10%
difference (same trend) observed on both slides, and high
stringency setting represents >15% difference (same trend)
observed on both slides.
Western Blot Analysis
The antibody array is a multiplexed platform which might
be more susceptible to interferences than single immuno-
assays. To affirm the validity of our findings, we performed
western blot analysis on one selected antigen, cathepsin D,
to see if we could duplicate the expression pattern observed
on antibody array. Monoclonal antibody against cathepsin
D was obtained from BD Biosciences (CA, USA), the same
antibody provider for the production of Clontech Antibody
Microarrays.
NAF protein (3 µg) were separated on a precast 4–12%
SDS Bis–Tris gel along with a protein size standard with
molecular weights ranging from 3 to 185 kD (Invitrogen,
CA, USA). The protein was transferred onto PVDF
membrane using XCell blotting module (Invitrogen, CA,
USA) for 1 h. Membranes were blocked overnight at 4°C in
PBS-T buffer (1× PBS with 0.05% Tween-20) containing
5% nonfat milk. After blocking, the membranes were
incubated at room temperature for 1 h with the primary
antibody obtained from BD Biosciences. The membrane
was then washed with PBS-T 5 min three times and
incubated with secondary antibody conjugated with horse-
radish peroxidase (rabbit anti-mouse IgG, Pierce, WI, USA)
for 1 h at room temperature. The membranes were washed
again in PBS-T, and the bound antibody was illuminated
with a SuperSignal West Femoto Maxium kit (Pierce, WI,
USA). The blot image was recorded using ChemiDoc XRS
(Bio-Rad, CA, USA).
Results and Discussion
Determination of Experimental Variability and Biological
Variability Between Paired Breasts of Assumed Healthy
Women
Prior to the analysis of cancer specimens, we performed
self-to-self and left-to-right comparisons using control
samples. These two experiments were to establish the
experimental variations (self-to-self) and the biological
variability between the normal paired breasts (left-to-right).
The same sample (self-to-self) was labeled with green
and red dye to determine experimental variability. Eleven
proteins were listed as differentially expressed at low
stringency (>10% change on one slide), one at medium
stringency (>10% change on reciprocal slides, same trend),
and zero at high stringency (>15% change on reciprocal
slides, same trend). The experimental noise can be filtered
using the 15% stringency filter.
The normal biological variability in the matched fluids
of the same healthy individual was determined by a left-to-
right comparison. Two normal subjects were studied. Using
the 15% stringency filter, three proteins were listed as
differentially expressed in one pair of sample and two
proteins were listed as differentially expressed in the other
pair.
Based on these two experiments, we set the selection
criteria for “difference” as >15% change on reciprocal
slides, same trend. At this cutoff, none of the 512 proteins
were found differently expressed in the self-to-self exper-
iment; minimal number of proteins (two and three,
respectively) was flagged as differentially expressed in the
two left-to-right experiments. Although a more stringent
setting could potentially reduce the normal biological
variations between paired breasts to zero, we chose this
moderate setting as it would not eliminate too many of the
candidate biomarkers at the initial screening step.
Differential Analysis Between Affected-To-Unaffected
Breasts of the Same Cancer Patient
We have analyzed paired NAF samples from 18 patients
(13 invasive cancers, two DCIS, and three ADH). An
example of the array images is shown in Fig. 1. C3e8 and
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C3f8 are duplicate spots of antibody against protein kinase C,
delta. C3g8 and C3h8 are duplicate spots of antibody against
protein tyrosine kinase 2 beta (PTK2B). Two slides were
generated from each pair of NAF by dye-swap (subject 30,
healthy control, slides A and B; subject 50, invasive cancer in
the right breast, slides C and D). No difference was observed
on both antigens between left-to-right breasts of the control
subject; spots appear yellow. Higher expression of PTK2B
was observed in the affected breast of the cancer patient; spots
appear red on one slide, green on the other.
In contrast to the relatively constant pattern of protein
expressions between the normal paired breasts, there are a
much greater number of changes observed in the tumor
associated NAF samples. Using the selected stringency
filter of 15%, the number of differentially expressed
antigens varied between 10 and 72 in the tumor-
associated NAF samples. There is also an apparent
patient-to-patient variability when we compare the list of
the differentially expressed proteins, suggesting a highly
variable tumor microenvironment patient-to-patient.
Selection of High Rank Antigens that is Prevalent
Among Patients
To identify antigens that are prevalent across patients, we
compiled all candidate antigens from 18 patients and
ranked them based on a calculated probability score PS
(PS=N+−N−, N+, number of patients with elevated antigen
in the affected breast; N−, number of patients with reduced
antigen in the affected breast). This ranking was done
automatically using an in-house computer program that was
developed for this application.
As presented in Table 2, the best-ranked antigen is NME.
This protein has an N+ of 6 (elevated in the affected breast
of six patients), an N− of 0 (zero patient showed reversed
expression pattern), which resulted a probability score of 6.
Going down the list, the probability of a candidate antigen
as a potential biomarker is getting lower, as reverse
expression patterns for the same protein are observed in
different patients. There are 14 antigens with a probability
score >=0, among them eight has a score of 4 and higher.
These eight antigens were selected as candidate biomarkers
for further evaluations.
Differential Expression Pattern of Cathepsin D Detected
by Antibody Array Analysis can be Validated
by Western Blot
The validity of the protein expression patterns detected by the
antibody array analysis was tested by western blot. Limited by
the volume of each NAF sample and the detection sensitivity
of the western blot analysis, we decided to use cathepsin D as
a model protein for this study. Among all antigens tested on
the antibody array, cathepsin D is the most abundant based on
its fluorescence signal. We obtained monoclonal antibody
against cathepsin D from BD Biosciences (CA, USA), the
Fig. 1 Magnified array images
showing differentially expressed
antigens. C3e8 and C3f8 are
duplicate spots of antibody
against protein kinase C, delta.
C3g8 and C3h8 are duplicate
spots of antibody against protein
tyrosine kinase 2 beta (PTK2B).
Two slides were generated from
each pair of NAF by dye-swap
(subject 30, healthy control,
slides A and B; subject 50,
invasive cancer in right breast,
slides C and D). No difference
was observed on either antigen
between left-to-right breasts of
the control subject; spots appear
yellow. Higher expression of
PTK2B was observed in the
affected breast of the cancer
patient; spots appear red on one
slide, green on the reciprocal
slide
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same antibody provider for the production of Clontech
Antibody Microarrays.
Based on the antibody array analysis, cathepsin D is
elevated in the affected breast of patient 48, 50, and 72 and
showed a reverse pattern in patient 39, 80, and 84 (Table 2).
Consistent with this pattern, we detected cathepsin D bands
in the three tumor-associated samples with elevated
fluorescent signals, but no appreciable band in their
contralateral controls (Fig. 2). As also expected, we could
not detect any appreciable band from the paired samples of
the normal control, as well as of patient 80, whose affected
breast showed lower cathepsin D signal on antibody arrays.
Table 2 Summary of candidate biomarkers





Supporting evidence for elevated protein expression
in breast cancer tissue
Nonmetastatic cells
1 protein
NME1 Cytoplasm/Extracellular Novel Overall expression Cancer>Normal
Stain positive in glandular cells in normal breast,
strong cytoplasmic/membrane staining in cancer
{Uhlen, 2005 #36}{Lacombe, 1991 #79}
Protein tyrosine kinase
2 beta
PTK2B Cytoplasm Novel NA
Arrestin beta 1 ARRB1 Cytoplasm Novel Overall expression Cancer>Normal
In breast, malignant tissue showed a few cases of
moderate to strong staining in contrast to the
normal tissue that was negative.
{Uhlen, 2005 #36}
Rho interacting protein 3 MRIP Cytoplasm Novel NA
GDNF family receptor
alpha 1
GFRA1 Cell membrane Novel Overexpression in a subset of estrogen receptor-
positive tumors
{Esseghir, 2007 #78}
Adenomatosis polyposis coli APC Cytoplasm Novel NA
Heat shock 60 kDa
protein 1 (chaperonin)
HSP60 Extracellular Novel HSP60 expression gradually increases from
normal through DCIS to invasive tissues.
Autoantibodies directed against HSP60 were
present in 16/49 (31%) early stage breast




SLP76 Cytoplasm Novel NA
Cathepsin Da CTSD Extracellular In normal pooled NAF
{Varnum, 2003 #30}
Overall expression Cancer>Normal
Stain positive in glandular cells in normal breast
Heterogeneous staining pattern in cancer, often
diffuse, slight to moderate cytoplasmic
{Uhlen, 2005 #36}
NA information not available
a Cathepsin D is included in this table for reference to the western blot analysis in Fig. 1, not as a candidate biomarker
L        R L        R* L*       R
05 50 72 8048
L*        R L        R*
Array
Western
Control Patient PatientPatient Patient
Anti-CATD
+++ +++ +++ - - -
Fig. 2 Expression pattern of cathepsin D detected by antibody array
can be validated by western blot. Equal amounts of NAF protein
(3 µg) were separated on a precast 4–12% SDS Bis–Tris gel.
Cathepsin D was detected using monoclonal antibody from BD
Biosciences. Samples from four patients and one control were studied.
Single asterisk indicates tumor-associated NAF, triple plus signs
indicate elevated expression detected by antibody array, broken line
indicates decreased expression detected by antibody array
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Four of the Selected NAF Markers are Supported
by Published Immunohistochemistry Studies on Breast
Cancer Tissues
We did an extensive literature search to obtain more
information on these candidate proteins. The searched
database included the human protein reference data base
(www.hprd.org), the human protein atlas (www.proteinatlas.
org), and reference database PubMed.
The subcellular localizations of the candidate proteins
are diverse. NM23A and HSP60 can be found extracellu-
larly, GFRA1 is primarily membrane bound, and PTK2B,
ARRB1, MRIP, and SLP76 are primarily cytoplasmic. As
proteins in NAF can be either secreted or as a result of cell
lysis, observation of both intracellular, membrane bound,
and extracelluar proteins in NAF are not surprising and
have been previously reported by others [8].
Several of the candidate proteins have been studied by
immunohistochemistry in breast cancer tissues. NM23A,
ARRB1, GFRA1, and HSP60 [15–17] are elevated in
breast cancer tissue, supporting the observed elevated
protein level in cancer associated NAF (Table 2). Addition-
ally, HSP60 has been identified as tumor-associated antigen,
autoantibodies directed against HSP60 were present in 16/49
(31%) early stage breast cancer and 18/58 (32.6%) DCIS
patients, compared to 4/93 (4.3%) healthy subjects [17]. The
protein candidates without existing tissue data will be
validated in future studies.
Concluding Remarks
Nipple aspiration fluid is a rich source of breast cancer
biomarkers. The unique anatomical feature of the breast as
a paired organ also makes it a perfectly matched case and
control system not confounded by interindividual variabil-
ity. However, due to the limited fluid production from each
breast, comprehensive proteomics analysis is difficult to
achieve using conventional top–down approach. To over-
come the limitation on sample quantity, we explored the
utility of a targeted approach that takes advantage of the
technology advancement on nanoscale two-color labeling
and high-content antibody microarrays. This approach is
proven effective; we were able to perform differential
analysis on 512 proteins in matched NAF samples, the
largest number of proteins ever surveyed in NAF.
Based on results obtained from 18 patients with early
stage breast cancer and precancerous lesions, we made the
following observations: (1) There are appreciable protein
changes in NAF at the very early stage of the tumor
development. (2) The differentially expressed proteins are
different patient-to-patient, suggesting a highly variable
tumor microenvironment. (3) We did not find a single
biomarker that could recognize all 18 patients. The best
marker identified in this pilot study has a sensitivity of 33%
(6/18). Knowing breast cancer is highly heterogeneous, this
result is expected, and our anticipation is to find a good
combination of several of these biomarkers that jointly
could offer a much more desirable sensitivity.
We provided initial validation studies on our findings.
The validity of the antibody array findings was affirmed by
single immunoassay on western blot, and elevated expres-
sion of four of the selected markers in NAF is supported by
published immunohistochemistry studies on breast cancer
tissues. With this, we are confident to move on to the next
stage of the tissue validation studies, as well as testing the
markers in a larger cohort of NAF samples. As the scope of
this biomarker screening is limited to the content of the
antibody arrays, we also anticipate that more protein
abnormalities can be discovered when new generation of
the arrays become available.
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